The research collaboration will combine PeptiDream’s proprietary peptide library with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D. The financial terms of the agreement are not disclosed. In exchange for world-wide rights to the therapeutic peptides resulting from the collaboration, Ipsen will make an upfront payment to PeptiDream and pay R&D and commercialization costs. PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
“Our partnership with Ipsen to discover novel therapeutic peptides for serious debilitating disease reinforces the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide,” said Patrick Reid, Ph.D., Chief Scientific Officer and Head of PeptiDream's discovery programs.
“Ipsen and PeptiDream now enter into a research collaboration to discover novel highly-selective peptides targeting specific serious disease using the synergies of skills and competencies between both companies. We believe the Ipsen – PeptiDream agreement implements our philosophy to apply innovation for future patient care,” stated Dr. Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen.